GlassScriptPhysician profile
Kim T Baker
NPI 1912089624
$1,337.11
in general payments reported to CMS, 2019-2025
27 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $30.77 · 2021: $125 · 2022: $453 · 2023: $212 · 2024: $172 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $236.55 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $181.01 | 2019-2025 | |
| Abbvie INC. | $144.72 | 2021-2023 | Ubrelvy |
| Intuitive Surgical, INC. | $97.24 | 2022 | |
| Amgen INC. | $63.21 | 2023-2025 | Evenity, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $49.17 | 2022-2025 | Delstrigo, Pifeltro, Dificid |
| Sanofi-Aventis U.S. LLC | $47.58 | 2022 | |
| Sunovion Pharmaceuticals INC. | $41.13 | 2022 | |
| Xeris Pharmaceuticals, INC. | $38.54 | 2023-2024 | Gvoke Hypopen |
| Angiodynamics, INC. | $36.40 | 2021 | |
| Boston Scientific Corporation | $35.74 | 2021-2023 | Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $35.41 | 2025 | Libtayo |
| Allergan, INC. | $33.21 | 2019-2020 | |
| Lilly USA, LLC | $33.15 | 2022-2024 | Mounjaro |
| Radius Health, INC. | $31.64 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.91 | 2023-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $26.01 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $24.82 | 2023 | Gemtesa |
| Abbott Laboratories | $24.33 | 2022 | |
| Viiv Healthcare Company | $23.75 | 2022 | |
| Dynavax Technologies Corporation | $21.46 | 2022 | |
| Novo Nordisk INC | $16.32 | 2023 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $14.79 | 2023 | Quviviq |
| Astellas Pharma US INC | $14.09 | 2023 | Veozah |
| Phadia US INC. | $14.03 | 2019 | |
| Nestle Healthcare Nutrition INC. | $11.96 | 2022 | |
| Therapeuticsmd, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.